LEXX insider transaction filings
Lexaria Bioscience Corp. — 31 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-03-18. Screen LEXX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for LEXX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Lexaria Bioscience Corp.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-18 | 4 | BUNKA CHRISTOPHER — Director | Gift (G): 100,000 @ $0 | EDGAR |
| 2025-07-30 | 4 | McKechnie William Edward — Director | Purchase (P): 5,000 @ $0.91 | EDGAR |
| 2025-07-30 | 4 | DOCHERTY JOHN MARTIN — President & CSO, Director | Purchase (P): 5,376 @ $0.93 | EDGAR |
| 2025-07-30 | 4 | Carle Vanessa — Secretary | Purchase (P): 750 @ $0.91 | EDGAR |
| 2025-07-30 | 4 | CHRISTOPHER RICHARD — Chief Executive Officer, Director | Purchase (P): 15,000 @ $0.91 | EDGAR |
| 2025-07-30 | 4 | BUNKA CHRISTOPHER — Director | Purchase (P): 15,600 @ $0.92 · Purchase (P): 11,900 @ $0.91 | EDGAR |
| 2025-05-16 | 4 | Carle Vanessa — Secretary | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | DOCHERTY JOHN MARTIN — President, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Shankman Michael Elliot — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Bhullar Baljinder — Director | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | McKechnie William Edward — Director | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Baxter Nicholas W — Director | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | CHRISTOPHER RICHARD — Chief Executive Officer, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | REESE ALBERT L JR — Director | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | BUNKA CHRISTOPHER — Director | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | BUNKA CHRISTOPHER — Director | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2024-12-03 | 4 | CHRISTOPHER RICHARD — Chief Executive Officer | Purchase (P): 22,828 @ $2.24 · Purchase (P): 27,172 @ $2.47 | EDGAR |
| 2024-08-13 | 4 | TURKEL CATHERINE C. — Director | Purchase (P): 1,600 @ $3.13 | EDGAR |
| 2024-08-01 | 4 | Carle Vanessa — Secretary | Sale (S): 2,567 @ $4 | EDGAR |
| 2024-07-30 | 4 | TURKEL CATHERINE C. — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-07-30 | 4 | McKechnie William Edward — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-07-30 | 4 | Baxter Nicholas W — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-07-30 | 4 | REESE ALBERT L JR — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-05-15 | 4 | Carle Vanessa — Secretary | Option exercise (M): 2,500 @ $1.15 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Carle Vanessa — Secretary | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | TURKEL CATHERINE C. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | McKechnie William Edward — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | DOCHERTY JOHN MARTIN — President, Director | Grant/award (A): 49,500 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Baxter Nicholas W — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | REESE ALBERT L JR — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | BUNKA CHRISTOPHER — Chief Executive Officer, Director | Grant/award (A): 49,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Lexaria Bioscience Corp.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-17 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-10 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-07-30 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-06 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-28 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-12-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-25 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LEXX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →